Genmab Balance Sheet Health
Financial Health criteria checks 6/6
Genmab has a total shareholder equity of DKK31.9B and total debt of DKK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are DKK39.7B and DKK7.7B respectively. Genmab's EBIT is DKK6.6B making its interest coverage ratio -6.6. It has cash and short-term investments of DKK17.3B.
Key information
0%
Debt to equity ratio
DKK 0
Debt
| Interest coverage ratio | -6.6x |
| Cash | DKK 17.32b |
| Equity | DKK 31.92b |
| Total liabilities | DKK 7.74b |
| Total assets | DKK 39.66b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GE91's short term assets (DKK23.7B) exceed its short term liabilities (DKK4.6B).
Long Term Liabilities: GE91's short term assets (DKK23.7B) exceed its long term liabilities (DKK3.2B).
Debt to Equity History and Analysis
Debt Level: GE91 is debt free.
Reducing Debt: GE91 has not had any debt for past 5 years.
Debt Coverage: GE91 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GE91 has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 09:47 |
| End of Day Share Price | 2024/11/15 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genmab A/S is covered by 45 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Carlsen | ABG Sundal Collier |
| Armelle Moulin | AlphaValue |
| Emily Field | Barclays |